The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1

Mutations in leucine-rich repeat kinase 2 gene (LRRK2) are associated with familial and sporadic Parkinson’s disease (PD). LRRK2 is a complex protein that consists of multiple domains, including 13 putative armadillo-type repeats at the N-terminus. In this study, we analyzed the functional and molecular consequences of a novel variant, E193K, identified in an Italian family. E193K substitution does not influence LRRK2 kinase activity. Instead it affects LRRK2 biochemical properties, such as phosphorylation at Ser935 and affinity for 14-3-3ε. Primary fibroblasts obtained from an E193K carrier demonstrated increased cellular toxicity and abnormal mitochondrial fission upon 1-methyl-4-phenylpyridinium treatment. We found that E193K alters LRRK2 binding to DRP1, a crucial mediator of mitochondrial fission. Our data support a role for LRRK2 as a scaffolding protein influencing mitochondrial fission.

[1]  M. Cookson,et al.  PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2 , 2017, Front. Mol. Neurosci..

[2]  C. Chu,et al.  Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants , 2017, The Journal of Neuroscience.

[3]  E. Kremmer,et al.  The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions , 2017, Scientific Reports.

[4]  A. Dillman,et al.  The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. , 2017, The Biochemical journal.

[5]  G. Gao,et al.  Dysregulation of autophagy and mitochondrial function in Parkinson’s disease , 2016, Translational Neurodegeneration.

[6]  G. Piccoli,et al.  LRRK2 Regulates Voltage-Gated Calcium Channel Function , 2016, Front. Mol. Neurosci..

[7]  Matthias Mann,et al.  Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases , 2016, eLife.

[8]  M. Cookson,et al.  Leucine‐rich repeat kinase 2 interacts with p21‐activated kinase 6 to control neurite complexity in mammalian brain , 2015, Journal of neurochemistry.

[9]  Wenzhang Wang,et al.  Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes , 2015, Nature Medicine.

[10]  B. Hoffer,et al.  Mitochondria: A Therapeutic Target for Parkinson’s Disease? , 2015, International journal of molecular sciences.

[11]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[12]  J. M. Bravo-San Pedro,et al.  G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. , 2014, Toxicology.

[13]  F. Mastaglia,et al.  Evidence that the LRRK2 ROC domain Parkinson's disease‐associated mutants A1442P and R1441C exhibit increased intracellular degradation , 2014, Journal of neuroscience research.

[14]  H. Aslan.  Türkiye'de sporadik Parkinson Hastalığı Olan Hastalarda LRRK2 Geni G2019S Mutasyonunun Araştırılması , 2014 .

[15]  C. Kiel,et al.  Leucine-Rich Repeat Kinase 2 Binds to Neuronal Vesicles through Protein Interactions Mediated by Its C-Terminal WD40 Domain , 2014, Molecular and Cellular Biology.

[16]  A. Singleton,et al.  LRRK2: Cause, Risk, and Mechanism , 2014, Journal of Parkinson's disease.

[17]  T. Dawson,et al.  Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily , 2013, Human molecular genetics.

[18]  K. Scearce-Levie,et al.  Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations , 2012, Science Translational Medicine.

[19]  Heung-Chin Cheng,et al.  Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. , 2012, Biochemical Society transactions.

[20]  M. Cookson,et al.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. , 2012, The Biochemical journal.

[21]  S. C. Chafe,et al.  Mutations in the Profilin 1 Gene Cause Familial Amyotrophic Lateral Sclerosis , 2012, Nature.

[22]  Xiongwei Zhu,et al.  LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. , 2012, Human molecular genetics.

[23]  Xiongwei Zhu,et al.  DLP1‐dependent mitochondrial fragmentation mediates 1‐methyl‐4‐phenylpyridinium toxicity in neurons: implications for Parkinson’s disease , 2011, Aging cell.

[24]  C. Magnani,et al.  Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  O. Shupliakov,et al.  Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission , 2011, The EMBO journal.

[26]  P. Blain,et al.  Mitochondrial Dysfunction in Parkinson's Disease , 2011, Parkinson's disease.

[27]  W. Wurst,et al.  LRRK2 Controls Synaptic Vesicle Storage and Mobilization within the Recycling Pool , 2011, The Journal of Neuroscience.

[28]  L. Scorrano,et al.  During autophagy mitochondria elongate, are spared from degradation and sustain cell viability , 2011, Nature Cell Biology.

[29]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[30]  E. Bailes,et al.  Armadillo-repeat protein functions: questions for little creatures. , 2010, Trends in cell biology.

[31]  A. Reith,et al.  Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization , 2010, The Biochemical journal.

[32]  A. Prescott,et al.  14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.

[33]  C. Blackstone,et al.  Dynamic regulation of mitochondrial fission through modification of the dynamin‐related protein Drp1 , 2010, Annals of the New York Academy of Sciences.

[34]  D. Petrey,et al.  The WD40 Domain Is Required for LRRK2 Neurotoxicity , 2009, PLoS ONE.

[35]  Yih-Ru Wu,et al.  LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi‐center pooled analysis , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[36]  M. Cookson,et al.  LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans , 2009, The Journal of Neuroscience.

[37]  O. Shirihai,et al.  Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. , 2008, Biochimica et biophysica acta.

[38]  M. Cookson,et al.  The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.

[39]  R. Roepman,et al.  A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.

[40]  Toshihiko Oka,et al.  Mitotic Phosphorylation of Dynamin-related GTPase Drp1 Participates in Mitochondrial Fission* , 2007, Journal of Biological Chemistry.

[41]  I. Marín.  The Parkinson disease gene LRRK2: evolutionary and structural insights. , 2006, Molecular biology and evolution.

[42]  P. Emson,et al.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain , 2006, Annals of neurology.

[43]  E. Tan.  Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. , 2006, Annals of the Academy of Medicine, Singapore.

[44]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[45]  C. Blackstone,et al.  Bax/Bak-Dependent Release of DDP/TIMM8a Promotes Drp1-Mediated Mitochondrial Fission and Mitoptosis during Programmed Cell Death , 2005, Current Biology.

[46]  M. Canesi,et al.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor , 2005, Journal of Medical Genetics.

[47]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[48]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[49]  Yuval Garini,et al.  From micro to nano: recent advances in high-resolution microscopy. , 2005, Current opinion in biotechnology.

[50]  K. Mihara,et al.  Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity , 2004, Journal of Cell Science.

[51]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[52]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[53]  L H Schaefer,et al.  Structured illumination microscopy: artefact analysis and reduction utilizing a parameter optimization approach , 2004, Journal of microscopy.

[54]  P. V. van Haastert,et al.  Roc, a Ras/GTPase domain in complex proteins. , 2003, Biochimica et biophysica acta.

[55]  M. Margaglione,et al.  No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age , 2003, Circulation.

[56]  P E Bourne,et al.  The Protein Data Bank. , 2002, Nucleic acids research.

[57]  Gert Vriend,et al.  Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field , 2002, Proteins.

[58]  Andrew J. Lees,et al.  Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.

[59]  A. M. van der Bliek,et al.  Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. , 2001, Molecular biology of the cell.

[60]  M. Hess,et al.  Cryopreparation provides new insight into the effects of brefeldin A on the structure of the HepG2 Golgi apparatus. , 2000, Journal of structural biology.

[61]  J. Thornton,et al.  AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR , 1996, Journal of biomolecular NMR.

[62]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[63]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[64]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[65]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[66]  Y. Gilad,et al.  LRRK 2 regulates mitochondrial dynamics and function through direct interaction with DLP 1 , 2012 .

[67]  E. Gnaiger,et al.  High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. , 2012, Methods in molecular biology.

[68]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[69]  Simon C Watkins,et al.  Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. , 2007, The American journal of pathology.

[70]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[71]  D. Studer,et al.  High pressure freezing comes of age. , 1989, Scanning microscopy. Supplement.